Prosecution Insights
Last updated: November 20, 2026
Application No. 18/678,592

METHODS FOR DOUBLE-STRANDED SEQUENCING BY SYNTHESIS

Non-Final OA §102§DOUBLEPATENT
Filed
May 30, 2024
Priority
May 31, 2023 — provisional 63/470,050
Examiner
YU, TIAN NMN
Art Unit
1681
Tech Center
1600 — Biotechnology & Organic Chemistry
Assignee
Illumina Inc.
OA Round
1 (Non-Final)
56%
Grant Probability
Moderate
1-2
OA Rounds
1y 4m
Est. Remaining
76%
With Interview

Examiner Intelligence

Grants 56% of resolved cases
56%
Career Allowance Rate
52 granted / 92 resolved
-3.5% vs TC avg
Strong +19% interview lift
Without
With
+19.3%
Interview Lift
resolved cases with interview
Typical timeline
3y 9m
Avg Prosecution
66 currently pending
Career history
169
Total Applications
across all art units

Statute-Specific Performance

§101
11.1%
-28.9% vs TC avg
§103
31.0%
-9.0% vs TC avg
§102
17.5%
-22.5% vs TC avg
§112
30.6%
-9.4% vs TC avg
Black line = Tech Center average estimate • Based on career data from 92 resolved cases

Office Action

§102 §DOUBLEPATENT
DETAILED ACTION Notice of Pre-AIA or AIA Status The present application, filed on or after March 16, 2013, is being examined under the first inventor to file provisions of the AIA . Information Disclosure Statement The information disclosure statements (IDS) submitted on 05/01/2025; 04/21/2026 are in compliance with the provisions of 37 CFR 1.97. Accordingly, the information disclosure statement is being considered by the examiner. Status of Claims This office action is in response to Applicant's Response to Election/Restriction filed on September 18, 2026. No claims amendment are made in the response filed on 09/18/2026. The latest version of the claims is Claim Amendment filed on - 08/06/2024. Claims 45-64 are currently pending, with claims 54-64 withdrawn. Claims 45-53 are under examination. This is the first action on the merits. Claim Objections Claim 45 is objected to because of the following informalities: • In claim 45, lines 3-4, "a second oligonucleotide strand hybridized to the first nucleotide strand" should read "a second oligonucleotide strand hybridized to the first oligonucleotide strand." Election/Restrictions Applicant's election with traverse of the following species in the reply filed on September 18, 2026 is acknowledged: Species of sequencing method: A) sequencing method using nick translation as shown in FIG. 5B (claim 45; consistent with FIG.1)1. Applicant's traversal is on the ground that "the generic claim includes sufficiently few species that a search and examination of all the species at one time would not impose a serious burden on the Examiner." (Remarks, page 5). This is not found persuasive. As noted in the restriction requirement, no claim is generic to the identified species (see Response to Election / Restriction Filed - 09/18/2026, page 3). Applicant's remarks refers to a generic claim but does not identify any claim that is generic to the species. Accordingly, Applicant's argument is not applicable to the restriction requirement as set forth and does not establish that the requirement is improper. In this instant case, the requirement for species election is properly made. As stated in the restriction requirement (mail date 07/29/2026), and reiterated here: The species are independent or distinct because the different species recite separate characteristics of such species, and there is no disclosure of relationship between species (see MPEP § 806.04(b)). In addition, these species are not obvious variants of each other based on the current record. The species necessitate separate searches, leading to serious search and/or examination burden (see MPEP § 808.01(a)) because the Species of sequencing method reflect alternative method embodiments in the disclosure, requiring different steps and materials, resulting in separate searches. There is a serious search and/or examination burden for the patentably distinct species as set forth above because at least the following reason(s) apply: The species require a different field of search (e.g., searching different classes/subclasses or electronic resources, or employing different search queries); and/or the prior art applicable to one species would not likely be applicable to another species; and/or the species are likely to raise different non-prior art issues under 35 U.S.C. 101 and/or 35 U.S.C. 112, first paragraph. Therefore, these species in the species of method are directed to independent and patentably distinct inventions, and there would be a serious search and/or examination burden if species election is not required. The requirement is still deemed proper and is therefore made FINAL. Claims 54-64 are withdrawn from further consideration pursuant to 37 CFR 1.142(b) as being drawn to a nonelected invention. Claims 45-53 are under consideration. Priority The priority date of the instant claims 45-51 is 05/31/2023, filling date of the US provisional application NO. 63/470,050. Regarding claims 52-53, the earliest priority is 05/30/2024, the filling date of the instant U.S. nonprovisional application, because the instant application is the first to disclose a flap nuclease operably linked to a second protein, wherein the second protein comprises a "sequence-nonspecific DNA binding domain." Claim Interpretation In evaluating the patentability of the claims presented in this application, claim terms have been given their broadest reasonable interpretation (BRI) consistent with the specification, as understood by one of ordinary skill in the art, as outlined in MPEP§ 2111. For the purpose of applying prior art, the recitation "sequencing … as the primer is extended" in claim 45 is interpreted under BRI as sequencing that occurs during the course of primer extension. The language is construed as not require sequencing (e.g., detecting nucleotide incorporation to determine the template sequence) to occur simultaneously with primer extension. Rather, sequencing may occur at any time while the primer-extension process is ongoing. For example, this interpretation encompasses sequencing-by-synthesis methods in which primer extension and detection occur in successive steps or cycles, such that the sequence is progressively determined as the primer is extended. For the purpose of applying prior art, claim 45 recites “a free 3′ end of the primer.” Under BRI and in light of the specification, a “free 3′ end” is interpreted as a 3’ end that is not attached or bound to a surface. This interpretation is consistent with the specification. Para.[0052] describes a “surface oligonucleotide is attached through the surface at the 5′ end and has a free 3′ end.” Similarly, para.[0093] describes an unbound template as “free.” Accordingly, the term “free” within the claimed context is interpreted as referring to the absence of attachment or binding to a surface. For the purpose of applying prior art, claim 45 recites “sequencing by synthesis,” which is not expressly defined in the application’s disclosure. Accordingly, under BRI and based on the commonly understood meaning by one of ordinary skill in the art 2, “sequencing by synthesis” is interpreted as encompassing polynucleotide synthesis reactions in which the reaction products are measured to obtain nucleic acid sequence information. Claim Rejections - 35 USC § 102 In the event the determination of the status of the application as subject to AIA 35 U.S.C. 102 and 103 (or as subject to pre-AIA 35 U.S.C. 102 and 103) is incorrect, any correction of the statutory basis (i.e., changing from AIA to pre-AIA ) for the rejection will not be considered a new ground of rejection if the prior art relied upon, and the rationale supporting the rejection, would be the same under either status. The following is a quotation of the appropriate paragraphs of 35 U.S.C. 102 that form the basis for the rejections under this section made in this Office action: A person shall be entitled to a patent unless – (a)(2) the claimed invention was described in a patent issued under section 151, or in an application for patent published or deemed published under section 122(b), in which the patent or application, as the case may be, names another inventor and was effectively filed before the effective filing date of the claimed invention. Claims 45-53 are rejected under 35 U.S.C. 102(a)(2) as being anticipated by Boutell 3(WO2023126457A1- Methods of nucleic acid sequencing using surface-bound primers; effective filing date December 28 2022; Published on 2023-07-06). PNG media_image1.png 700 570 media_image1.png Greyscale Regarding claim 45, Boutell teaches a nucleotide sequencing method comprising: (a) providing a surface-bound double-stranded oligonucleotide complex (FIG. 5; [0203]-[0204]) comprising a first oligonucleotide strand (FIG. 5, 20; [0204] “a first surface oligonucleotide 20”), a second oligonucleotide strand hybridized to the first nucleotide strand (FIG. 5, 3O'b(c); [0204]), and a primer hybridized to the first oligonucleotide strand (FIG. 5, 41; [0204] second surface primer 41), wherein the first oligonucleotide strand has a 5′ end bound to a surface (FIG. 5, 20; [0204] “The first surface oligonucleotide 20 is bound to the surface 15 at its 5' end”), and wherein a free 3′ end of the primer is hybridized to a nucleotide of the first oligonucleotide strand that is 3′ of a nucleotide of the first oligonucleotide strand to which a 5′ end of the second oligonucleotide strand is hybridized (FIG. 5; [00207], the primer 41 has a free, extendable 3’ end hybridized to the 3’ end of first surface oligonucleotide 20, which also hybridizes to the 5’ end of 3O'b(c) ); (b) extending the primer from the free 3′ end using the first oligonucleotide strand as a template and sequencing at least a portion of the first oligonucleotide strand via sequencing by synthesis as the primer is extended (FIG. 5; [00207], “[00207] In step R of FIG. 5, at least a portion of the first polynucleotide template 30a is sequenced as the first read region 31. Sequencing may include sequencing by synthesis where the second surface primer 41 is enzymatically extended in the 5 ' to 3 ' direction thereby creating a portion of a second polynucleotide template 30 'a that is complementary to the first polynucleotide template 30a.”); and (c) nicking the second strand to remove a 5′ portion of the second strand before, during, or after one or more nucleotides are added to extend the primer in step (b) (FIG. 5; [00207], “In double stranded surface sequencing by nick translation, nucleotides on the strand ahead (cleaved fourth polynucleotide 3O'b(c)) of the growing first read region 31 are removed via nick translation”; see also [00211] –[00212]). Regarding claim 46, Boutell teaches wherein the second strand is nicked in step (c) before, during, or after each nucleotide is added to extend the primer in step (b) ([00211] “for every SBS incorporation cycle where a nucleotide is added onto the growing read strand 31, a flap nuclease removes one or more nucleotide on the cleaved fourth polynucleotide 3O'b(c).”; [0203] "the flap nuclease having endonuclease or exonuclease activity recognizes a nick or break in a single strand of the double stranded DNA and introduces a nick in the nicked strand at a location 3' of the recognized nick or break"). Regarding claim 47, Boutell teaches wherein the second strand is nicked in step (c) after more than one nucleotide is added to extend the primer in step (b) ([00211] “ a flap nuclease may prevent the formation and/or remove an impeding strand flap (i.e., one or more nucleotides forming a single strand of DNA that has been displaced from the template strand)”; [00212] “ flap nuclease is added after a number of sequencing cycles”). Regarding claim 48, Boutell teaches wherein nicking the second strand to remove a 5′ portion of the second strand comprises removing nucleotides and/or oligonucleotides from the second strand using a flap nuclease (FIG. 5; [00212] “After a predetermined number of SBS cycles where a flap has formed, a flap nuclease may be introduced to nick the cleaved fourth polynucleotide 3O'b(c) such that the displaced portion of the cleaved fourth polynucleotide 3O'b(c) is cleaved. ”). Regarding claim 49, Boutell teaches FEN1 ([000210] FEN1). Regarding claim 50, Boutell teaches wherein the flap nuclease is operably linked to a second protein ([00213] “a flap nuclease is operably linked to a DNA polymerase forming a polymerase-flap nuclease construct”). Regarding claim 51, Boutell teaches wherein the second protein comprises a polymerase ([00213] “a flap nuclease is operably linked to a DNA polymerase forming a polymerase-flap nuclease construct”). Regarding claims 52-53, they recite: 52. The method of claim 51, wherein the dsDNA binding domain comprises a sequence-nonspecific DNA binding domain. 53. The method of claim 52, wherein the DNA binding domain comprises Sso7d. Claims 52-53 are anticipated by Boutell because they do not further distinguish the claimed method from the prior art. Specifically, claims 52-53 further describe an alternative conditional limitation (e.g., a dsDNA binding domain) stemming from base claim 51, which requires only that one of the recited conditions be satisfied (e.g., "wherein the second protein comprises a polymerase or a dsDNA binding domain"). Claims 52-53 do not require the second protein to comprises a dsDNA binding domain. Rather, they merely further describe the dsDNA binding domain, which remains an alternative to "the second protein comprises a polymerase." Since Boutell teaches the required "second protein comprises a polymerase" condition of claim 51, as discussed above, the descriptive limitations for another alternative condition recited in claims 52-53 are not required to be met. Accordingly, Boutell anticipates claims 52-53. Double Patenting- Obvious Type The nonstatutory double patenting rejection is based on a judicially created doctrine grounded in public policy (a policy reflected in the statute) so as to prevent the unjustified or improper timewise extension of the “right to exclude” granted by a patent and to prevent possible harassment by multiple assignees. A nonstatutory double patenting rejection is appropriate where the conflicting claims are not identical, but at least one examined application claim is not patentably distinct from the reference claim(s) because the examined application claim is either anticipated by, or would have been obvious over, the reference claim(s). See, e.g., In re Berg, 140 F.3d 1428, 46 USPQ2d 1226 (Fed. Cir. 1998); In re Goodman, 11 F.3d 1046, 29 USPQ2d 2010 (Fed. Cir. 1993); In re Longi, 759 F.2d 887, 225 USPQ 645 (Fed. Cir. 1985); In re Van Ornum, 686 F.2d 937, 214 USPQ 761 (CCPA 1982); In re Vogel, 422 F.2d 438, 164 USPQ 619 (CCPA 1970); In re Thorington, 418 F.2d 528, 163 USPQ 644 (CCPA 1969). A timely filed terminal disclaimer in compliance with 37 CFR 1.321(c) or 1.321(d) may be used to overcome an actual or provisional rejection based on nonstatutory double patenting provided the reference application or patent either is shown to be commonly owned with the examined application, or claims an invention made as a result of activities undertaken within the scope of a joint research agreement. See MPEP § 717.02 for applications subject to examination under the first inventor to file provisions of the AIA as explained in MPEP § 2159. See MPEP § 2146 et seq. for applications not subject to examination under the first inventor to file provisions of the AIA . A terminal disclaimer must be signed in compliance with 37 CFR 1.321(b). The filing of a terminal disclaimer by itself is not a complete reply to a nonstatutory double patenting (NSDP) rejection. A complete reply requires that the terminal disclaimer be accompanied by a reply requesting reconsideration of the prior Office action. Even where the NSDP rejection is provisional the reply must be complete. See MPEP § 804, subsection I.B.1. For a reply to a non-final Office action, see 37 CFR 1.111(a). For a reply to final Office action, see 37 CFR 1.113(c). A request for reconsideration while not provided for in 37 CFR 1.113(c) may be filed after final for consideration. See MPEP §§ 706.07(e) and 714.13. The USPTO Internet website contains terminal disclaimer forms which may be used. Please visit www.uspto.gov/patent/patents-forms. The actual filing date of the application in which the form is filed determines what form (e.g., PTO/SB/25, PTO/SB/26, PTO/AIA /25, or PTO/AIA /26) should be used. A web-based eTerminal Disclaimer may be filled out completely online using web-screens. An eTerminal Disclaimer that meets all requirements is auto-processed and approved immediately upon submission. For more information about eTerminal Disclaimers, refer to www.uspto.gov/patents/apply/applying-online/eterminal-disclaimer. Claims 45-46 and 48-53 are provisionally rejected on the ground of nonstatutory double patenting as being unpatentable over claims 1, 2, 9-11 of copending Application No. 18/089,867 (reference application). Although the claims at issue are not identical, they are not patentably distinct from each other because the instant claims are anticipated by the claims (filed on 08/07/2026) of the '867 application. Instant claim 45 recites: A nucleotide sequencing method comprising: (a) providing a surface-bound double-stranded oligonucleotide complex (‘867 Application, claim 1) comprising a first oligonucleotide strand (‘867 Application, claim 1, first polynucleotide template covalently bound to the 3' end of the first surface oligonucleotide, the first surface oligonucleotide bound to the surface at a 5' end), a second oligonucleotide strand hybridized to the first nucleotide strand (‘867 Application, claim 2/1, fourth polynucleotide template complementary to the first polynucleotide template), and a primer hybridized to the first oligonucleotide strand (‘867 Application, claim 1, second surface primer), wherein the first oligonucleotide strand has a 5′ end bound to a surface (‘867 Application, claim 1, first polynucleotide template covalently bound to the 3' end of the first surface oligonucleotide, the first surface oligonucleotide bound to the surface at a 5' end), and wherein a free 3′ end of the primer is hybridized to a nucleotide of the first oligonucleotide strand that is 3′ of a nucleotide of the first oligonucleotide strand to which a 5′ end of the second oligonucleotide strand is hybridized (‘867 Application, claim 2/1, the cleaved fourth polynucleotide template producing the second surface primer and a cleaved fourth polynucleotide template having a free 5' end and a free 3' end); (b) extending the primer from the free 3′ end using the first oligonucleotide strand as a template and sequencing at least a portion of the first oligonucleotide strand via sequencing by synthesis as the primer is extended (‘867 Application, claim 1); and (c) nicking the second strand to remove a 5′ portion of the second strand before, during, or after one or more nucleotides are added to extend the primer in step (b) (‘867 Application, claim 10, polymerase is operably linked to the flap nuclease in a polymerase-flap nuclease construct, as the polymerase-flap nuclease construct is positioned at 3’ end of the extension end and 5’ end of the cleaved fourth polynucleotide template, a skilled artisan would have readily understood that it is the 5’ end of fourth polynucleotide template that is nicked by the flap nuclease ). Therefore, instant claim 45 is anticipated by claims 1-2 and 10 of the '867 application. Instant claims 48-53 are anticipated by claims 9-11 of the '867 application. This is a provisional nonstatutory double patenting rejection because the patentably indistinct claims have not in fact been patented. Prior Art Below are relevant prior art not used in rejection but pertinent to the claims or disclosure. Vijayan (US20170022553A1- Nucleic acid sequencing methods and systems; Published 2017-01-26) also teaches methods of sequencing of a surface-bound double-stranded oligonucleotide complex; see Example 10. Sequencing Double Stranded DNA by Nick Translation”; Horn(US20150368626A1- Polymerase Compositions, Methods of Making and Using Same ; Published on 2015-12-24) also teaches flap nuclease linked to a polymerase. Conclusion Claim 45 is objected to; claims 45-53 are rejected. No claims are allowed. Any inquiry concerning this communication or earlier communications from the examiner should be directed to TIAN NMN YU whose telephone number is (703)756-4694. The examiner can normally be reached Monday - Friday 8:30 am - 5:30 pm. Examiner interviews are available via telephone, in-person, and video conferencing using a USPTO supplied web-based collaboration tool. To schedule an interview, applicant is encouraged to use the USPTO Automated Interview Request (AIR) at http://www.uspto.gov/interviewpractice. If attempts to reach the examiner by telephone are unsuccessful, the examiner’s supervisor, Gary Benzion can be reached at (571) 272-0782. The fax phone number for the organization where this application or proceeding is assigned is 571-273-8300. Information regarding the status of published or unpublished applications may be obtained from Patent Center. Unpublished application information in Patent Center is available to registered users. To file and manage patent submissions in Patent Center, visit: https://patentcenter.uspto.gov. Visit https://www.uspto.gov/patents/apply/patent-center for more information about Patent Center and https://www.uspto.gov/patents/docx for information about filing in DOCX format. For additional questions, contact the Electronic Business Center (EBC) at 866-217-9197 (toll-free). If you would like assistance from a USPTO Customer Service Representative, call 800-786-9199 (IN USA OR CANADA) or 571-272-1000. /TIAN NMN YU/Examiner , Art Unit 1681 1 Claims 54-64 are withdrawn as being drawn to non-elected species B-E. 2 See Levy SE, Myers RM. Advancements in Next-Generation Sequencing. Annu Rev Genomics Hum Genet. 2016 Aug 31;17:95-115. doi: 10.1146/annurev-genom-083115-022413. Epub 2016 Jun 9. PMID: 27362342; page 98: “sequencing-by-synthesis reaction in which the products of the reaction are measured to produce sequencing data… . Sequencing-by-synthesis reactions performed by Illumina, Ion Torrent, Pacific Biosciences, and Roche 454 platforms utilize a polymerase reaction, whereas the former Applied Biosystems SOLiD platform and the Polonator platform use a ligation-mediated synthesis. “ See also data-science-sequencing; Lecture 2: Basics of DNA & Sequencing by Synthesis; Thursday 11 January 2018; pages 6-7. 3 Boutell qualifies as prior art under 35 U.S.C. 102(a)(2), because it has an effective filing date earlier than the effective filing date of the instant application. Boutell "names another inventor" (e.g. Jonathan Mark Boutell).
Read full office action

Prosecution Timeline

May 30, 2024
Application Filed
Nov 10, 2026
Non-Final Rejection mailed — §102, §DOUBLEPATENT (current)

Precedent Cases

Applications granted by this same examiner with similar technology

Patent 12767978
SYNTHETIC POLYNUCLEOTIDES AND METHODS FOR SELECTIVELY AMPLIFYING ALLELES
3y 2m to grant Granted Oct 20, 2026
Patent 12703882
METHODS OF SEQUENCING ANTIBODY CHAINS FROM HYBRIDOMAS AND KITS FOR PRACTICING SAME
6y 2m to grant Granted Aug 11, 2026
Patent 12698536
ROTAVIRUS GENOTYPE DETECTION METHOD, AND GENE AMPLIFICATION PRIMER SET USED IN SAME
4y 9m to grant Granted Aug 04, 2026
Patent 12686891
SILICA-BASED CHROMATOGRAPHIC PROCESSES FOR ISOLATING NUCLEIC ACID-PROTEIN COMPLEXES AND DETECTING TARGET NUCLEIC ACIDS
3y 1m to grant Granted Jul 21, 2026
Patent 12662702
SEQUENCING POLYNUCLEOTIDES USING NANOPORES
3y 9m to grant Granted Jun 23, 2026
Study what changed to get past this examiner. Based on 5 most recent grants.

Strategy Recommendation AI-generated — please review before filing

Get a prosecution strategy drawn from examiner precedents, rejection analysis, and claim mapping.
Typically takes 5-10 seconds — AI-generated, attorney review required before filing

Prosecution Projections

1-2
Expected OA Rounds
56%
Grant Probability
76%
With Interview (+19.3%)
3y 9m (~1y 4m remaining)
Median Time to Grant
Low
PTA Risk
Based on 92 resolved cases by this examiner. Grant probability derived from career allowance rate.

Sign in with your work email

Enter your email to receive a magic link. No password needed.

Personal email addresses (Gmail, Yahoo, etc.) are not accepted.

Free tier: 3 strategy analyses per month